• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Patrick Fisher Joins Orthofix as President of Global Orthopedics Business

    8/15/24 5:52:00 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care
    Get the next $OFIX alert in real time by email

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Patrick Fisher as President of the Orthofix Global Orthopedics business. In this role, Fisher will serve on the company's Executive Leadership team, reporting to Orthofix President and CEO Massimo Calafiore.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815706187/en/

    Patrick Fisher, President of Orthofix Global Orthopedics (Photo: Business Wire)

    Patrick Fisher, President of Orthofix Global Orthopedics (Photo: Business Wire)

    Fisher joins Orthofix from Stryker Corporation, a global medical technology company where he served as the Vice President and General Manager of the Foot and Ankle business unit. Prior to Stryker, Fisher served as the President of Lower Extremity and Biologics for Wright Medical, which was acquired by Stryker in 2020. After joining Wright Medical in 2002, he served in multiple roles of increasing responsibility including Vice President of U.S. Sales.

    "Patrick has led global teams in the successful development and execution of innovative strategies focused on driving commercial optimization across sales, marketing, R&D, clinical research and medical education," said Calafiore. "We are excited to welcome him to our team, and I am confident his leadership, experience and broad familiarity with the Orthopedics market will help us further grow this franchise and expand our market presence."

    "Orthofix has a uniquely differentiated orthopedics portfolio with a history of clinical innovation that goes back to its early beginnings in 1980," said Fisher. "I have long been aware of the great products and work done by the Orthofix orthopedics team, and I am honored to have the opportunity to lead this area of the organization. I look forward to working with the team to help drive growth and accelerate this important area of the business."

    Fisher has a Bachelor of Arts in International Studies from Rhodes College and a Master of Business Administration in International Business from the University of Memphis. Additionally, he is a board member of the Greater Memphis Medical Device Council, the Memphis Chairman's Circle and the University of Tennessee Research Advisory Board.

    As an inducement to enter into employment with Orthofix, Fisher was granted (i) performance-based vesting restricted stock units that settle into 30,637 shares of common stock at target achievement, (ii) time-based vesting restricted stock units that settle into 15,319 shares of common stock, and (iii) stock options to purchase 35,195 shares of common stock. The performance-based vesting restricted stock units vest at the end of a three-year performance period based on the Company's total stockholder return relative to an industry peer group index during such period, while the time-based vesting restricted stock units vest in equal tranches over three years. The stock options vest upon achievement of both service- and performance-based criteria, whichever is the later of (a) the date certain service-based conditions are met (which will be met over three years) and (b) the date that the average closing price of the Company's common stock over a one-month calendar period has been equal to or great than 150% of the closing price of the Company's common stock on the grant date. The grants, which were approved by Orthofix's Board of Directors, were made under standalone inducement award agreements approved pursuant to NASDAQ Marketplace Rule 5635(c)(4).

    About Orthofix

    Orthofix is a leading global spine and orthopedics company with a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions, and a leading surgical navigation system. Its products are distributed in more than 60 countries worldwide.

    The Company is headquartered in Lewisville, Texas, where it conducts general business, product development, medical education and manufacturing, and has primary offices in Carlsbad, CA, with a focus on spine and biologics product innovation and surgeon education, and Verona, Italy, with an emphasis on product innovation, production, and medical education for orthopedics. The combined Company's global R&D, commercial and manufacturing footprint also includes facilities and offices in Irvine, CA, Toronto, Canada, Sunnyvale, CA, Maidenhead, UK, Munich, Germany, Paris, France and São Paulo, Brazil.

    Forward-Looking Statements

    This news release may include forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "projects," "intends," "predicts," "potential," "continue" or other comparable terminology. Orthofix cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Each forward-looking statement contained in this news release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: the ability of newly launched products to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of robust clinical validation; and the risks identified under the heading "Risk Factors" in Orthofix Medical Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the Securities and Exchange Commission (SEC) on March 5, 2024. The Company's public filings with the SEC are available at www.sec.gov. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Orthofix does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240815706187/en/

    Get the next $OFIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OFIX

    DatePrice TargetRatingAnalyst
    1/22/2025$24.00Buy
    Canaccord Genuity
    11/8/2024$18.00 → $24.00Hold → Buy
    Stifel
    5/8/2024$15.00 → $20.00Neutral → Buy
    ROTH MKM
    10/20/2023$12.00Neutral
    ROTH MKM
    9/12/2023Buy → Neutral
    BTIG Research
    9/12/2023Buy → Hold
    Stifel
    7/19/2023$27.00Buy
    BTIG Research
    3/4/2022$41.00 → $45.00Hold → Buy
    Stifel
    More analyst ratings

    $OFIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Orthofix Medical Inc.

      SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)

      11/14/24 5:20:27 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Orthofix Medical Inc.

      SC 13G - Orthofix Medical Inc. (0000884624) (Subject)

      11/13/24 5:03:21 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Orthofix Medical Inc. (Amendment)

      SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)

      4/22/24 5:00:33 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Mcpherron Aviva claimed ownership of 50,050 shares (SEC Form 3)

      3 - Orthofix Medical Inc. (0000884624) (Issuer)

      5/9/25 4:24:43 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Large owner Engine Capital Management, Lp bought $1,231,000 worth of shares (100,000 units at $12.31) (SEC Form 4)

      4 - Orthofix Medical Inc. (0000884624) (Issuer)

      5/8/25 6:38:02 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • New insider Engine Capital Management, Lp claimed ownership of 4,151,671 shares (SEC Form 3)

      3 - Orthofix Medical Inc. (0000884624) (Issuer)

      5/8/25 6:34:36 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Orthofix Reports First Quarter 2025 Financial Results

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product lines. Highlights First quarter 2025 net sales of $193.6 million, including sales from its M6 artificial cervical and lumbar discs, and pro forma net sales of $189.2 million, excluding sales from its M6 discs, representing an increa

      5/6/25 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Engine Capital Nominates Two Highly Qualified and Independent Candidates for Election to Lyft's Board of Directors at the 2025 Annual Meeting

      Intends to File Preliminary Proxy Statement and Provides Overview of the Case for Shareholder-Driven Change at Lyft Following Years of Value Destruction Engine Capital LP (together with its affiliates, "Engine" or "we"), which owns approximately one percent of the outstanding common shares of Lyft, Inc. (NASDAQ:LYFT) ("Lyft" or the "Company"), today announced that it is filing a preliminary proxy statement in connection with its nomination of two highly qualified and independent candidates – Alan L. Bazaar and Daniel B. Silvers – for election to the Company's Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders (the "Annual Meeting"). Arnaud Ajdler, Founder and Port

      4/16/25 8:00:00 AM ET
      $AVID
      $FOR
      $HSON
      $IGT
      Computer Software: Prepackaged Software
      Technology
      Real Estate
      Finance
    • Orthofix to Report First Quarter 2025 Financial Results

      Company to Host Conference Call on Tuesday, May 6, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7524113. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Information O

      4/15/25 8:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Leadership Updates

    Live Leadership Updates

    See more
    • Orthofix Announces Appointment of Vickie Capps to Board of Directors

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312538957/en/Vickie Capps (Photo: Business Wire) "Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix," said Michael Finegan, Chairman of Orthofix. "Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously valuable perspective as we seek to deliver profitable growth and significa

      3/12/25 8:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Patrick Fisher Joins Orthofix as President of Global Orthopedics Business

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Patrick Fisher as President of the Orthofix Global Orthopedics business. In this role, Fisher will serve on the company's Executive Leadership team, reporting to Orthofix President and CEO Massimo Calafiore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815706187/en/Patrick Fisher, President of Orthofix Global Orthopedics (Photo: Business Wire) Fisher joins Orthofix from Stryker Corporation, a global medical technology company where he served as the Vice President and General Manager of the Foot and Ankle b

      8/15/24 5:52:00 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix Names Stephanie Walsh Chief Human Resources Officer

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Stephanie Walsh as Chief Human Resources Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716004057/en/Stephanie Walsh, Chief Human Resources Officer, Orthofix (Photo: Business Wire) A seasoned human resources executive, Walsh joins Orthofix from ResMed Inc., a San Diego-based medical device company, where she served most recently as Vice President of Transformation. During her tenure at ResMed, she also held multiple HR leadership positions including Vice President, People - SaaS, where she led the H

      7/16/24 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Engine Capital Management, Lp bought $1,231,000 worth of shares (100,000 units at $12.31) (SEC Form 4)

      4 - Orthofix Medical Inc. (0000884624) (Issuer)

      5/8/25 6:38:02 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • President & CEO Calafiore Massimo bought $172,801 worth of shares (9,914 units at $17.43), increasing direct ownership by 5% to 222,404 units (SEC Form 4)

      4 - Orthofix Medical Inc. (0000884624) (Issuer)

      3/6/25 4:27:08 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Orthofix Medical Inc.

      10-Q - Orthofix Medical Inc. (0000884624) (Filer)

      5/6/25 7:05:26 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Orthofix Medical Inc. (0000884624) (Filer)

      5/6/25 7:03:52 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Orthofix Medical Inc.

      DEFA14A - Orthofix Medical Inc. (0000884624) (Filer)

      4/30/25 4:15:12 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on Orthofix with a new price target

      Canaccord Genuity initiated coverage of Orthofix with a rating of Buy and set a new price target of $24.00

      1/22/25 7:47:50 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix upgraded by Stifel with a new price target

      Stifel upgraded Orthofix from Hold to Buy and set a new price target of $24.00 from $18.00 previously

      11/8/24 8:23:19 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix upgraded by ROTH MKM with a new price target

      ROTH MKM upgraded Orthofix from Neutral to Buy and set a new price target of $20.00 from $15.00 previously

      5/8/24 6:31:28 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Financials

    Live finance-specific insights

    See more
    • Orthofix Reports First Quarter 2025 Financial Results

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product lines. Highlights First quarter 2025 net sales of $193.6 million, including sales from its M6 artificial cervical and lumbar discs, and pro forma net sales of $189.2 million, excluding sales from its M6 discs, representing an increa

      5/6/25 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix to Report First Quarter 2025 Financial Results

      Company to Host Conference Call on Tuesday, May 6, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7524113. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Information O

      4/15/25 8:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance

      Record Results Reflect Strong Execution as Company Focuses on Most Profitable Growth Opportunities in Spine, Orthopedics and Bone Growth Therapies Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2024, and provided full-year 2025 financial guidance. Highlights Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compared to fourth quarter 2023 U.S. Spine Fixation1 net sales growth of 12% compared to fourth quarter 2023, driven by distribution expansion and further penetration in existing account

      2/25/25 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care